Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | PRKX | P51817 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | MST1R | Q04912 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26432855 | 0.81 | KMT2A (0.47) | IDO1KMT2ABRD4 | |
| SCHEMBL14614929 | 0.79 | PTGES (0.59) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL28917070 | 0.78 | CDK2 (0.56) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL26432911 | 0.77 | NPC1 (0.41) | KMT2A | |
| SCHEMBL23185459 | 0.76 | PLK4 (0.50) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL26432876 | 0.74 | CD38 (0.39) | KMT2A | |
| SCHEMBL24433138 | 0.74 | PLK4 (0.64) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL21496933 | 0.72 | CDK5 (0.45) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL14391753 | 0.71 | TDO2 (0.51) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL23413072 | 0.71 | CRBN (0.59) | PLK4CHEK1AURKADAPK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PLK4 1721/4885CHEK1 864/4885AURKA 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.